Similarly, inhibition of EGFR signalling decreases glucose consumption and the abundance of glycolytic and PPP metabolites in NSCLC cell lines (Makinoshima et al., 2014; Momcilovic et al., 2017). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.